skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

100+ Total results for product and free and sample content found

Scrip

Coronavirus Update: India Approves Remdesivir, Ex-Biogen Employee Charged

india-queue

A former employee of Biogen is officially charged in China for allegedly jeopardizing public health, Wuhan tests 10 million residents, India approves remdesivir.

Topic Coronavirus Vaccines

Scrip

Questions Remain On Gilead’s Remdesivir

Coronoavirus

Remdesivir shows ability to yield clinical improvement in moderately ill COVID-19 patients, but data are called ‘modest’ and shorter therapy duration showed better results than longer.

Topic Coronavirus Clinical Trials

Scrip

Merck’s Frazier Urges Businesses To Use ‘Every Instrument At Their Disposal’ To Reduce Racial Inequity

trial-diversity

‘What we have to guard against is that when the streets quiet down … a lot of people are going to go back to their normal lives,’ Merck CEO Ken Frazier says in an interview with CNBC.

Topic Leadership

Scrip

‘Business Unusual’: COVID-19 Brought Commercial Changes To Pharma And It May Stick

The pharmaceutical selling model will be modified even after the immediate COVID-19 pandemic crisis abates, the consulting firm ZS Associates predicts, citing new research.

Topic Coronavirus

Scrip

Coronavirus Update: Roche Launches Remdesivir Plus Actemra Trial, GSK Plans 1 Billion Vaccine Adjuvant Doses

Rio_de_Janeiro_Coronavirus

Roche is teaming up with Gilead on the combination trial, aiming to improve on results of remdesivir alone, which has failed to show mortality benefits in COVID-19 patients.

Topic Coronavirus

Pink Sheet

COVID-19 Staff Shakeup: Woodcock Moves to Commissioner's Office As Marks Drops Out Of 'Warp'

Restructuring-COVID-19

CBER Director Marks will no longer have to recuse himself from COVID-19 product reviews, a move seen as resoundingly positive by former senior FDA leaders. CDER Director Woodcock will now be free to focus solely on COVID-19 and bring her unique depth of agency experience to the Trump Administration's effort to speed development of vaccines, therapeutics and diagnostics for coronavirus.

Topic Coronavirus

Pink Sheet

What The Pandemic Can Teach Us About Running Clinical Trialssample content insights page

Coronavirus_stocks_shares_1658863093_1200

Participants in a recent webinar looked at how the coronavirus is changing the way we look at clinical trials and whether new EU COVID-19 guidance might hold lessons for future approaches to study design.

Topic Coronavirus

Scrip

Gilead’s Major Challenge Is Sustainable Model For Remdesivir

Coronavirus_Scrip

With efficacy data in hand, Gilead wants to balance economic sustainability with broad availability of remdesivir for COVID-19 patients. The firm did not alter guidance on Q1 earnings call.

Topic Coronavirus

Scrip

Pharma Can Reset Reputation In Pandemic Says Novartis CEO

virtual-smile

Vas Narasimhan hopes that donations and the "unprecedented collaborations" between drugmakers trying to overcome the COVID-19 pandemic is leading to a shift in the perception of the value of the sector to society.

Topic Coronavirus

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: